tiprankstipranks
Advertisement
Advertisement

HK:6160 Stock Latest News

BeOne Medicines Files U.S. Form S-8 to Expand Equity Incentive Plans
Company AnnouncementsBeOne Medicines Files U.S. Form S-8 to Expand Equity Incentive Plans
3d ago
6160
BeOne Medicines Shareholders Approve All AGM Resolutions and Refresh Board
PremiumCompany Announcements
BeOne Medicines Shareholders Approve All AGM Resolutions and Refresh Board
3d ago
6160
BeOne Medicines Sets Out Board and Committee Structure to Bolster Governance
PremiumCompany Announcements
BeOne Medicines Sets Out Board and Committee Structure to Bolster Governance
3d ago
6160
BeOne Medicines announces presentation of Phase 3 data in CLL patients
PremiumThe Fly
BeOne Medicines announces presentation of Phase 3 data in CLL patients
4d ago
ONC
BeOne Medicines Secures Multiple HKEX Rule Waivers to Support Flexible Financing and Partnerships
PremiumCompany Announcements
BeOne Medicines Secures Multiple HKEX Rule Waivers to Support Flexible Financing and Partnerships
4d ago
6160
BeOne Medicines Formalizes Compensation Committee Charter to Strengthen Governance
PremiumCompany AnnouncementsBeOne Medicines Formalizes Compensation Committee Charter to Strengthen Governance
4d ago
6160
BeOne Medicines Grants RSUs to 381 Employees Under Incentive Plan
Premium
Company Announcements
BeOne Medicines Grants RSUs to 381 Employees Under Incentive Plan
10d ago
6160
BeOne Medicines price target raised to $436 from $425 at RBC Capital
Premium
The Fly
BeOne Medicines price target raised to $436 from $425 at RBC Capital
12d ago
ONC
BeOne Medicines’ combination shows improved survival in adenocarcinoma
PremiumThe Fly
BeOne Medicines’ combination shows improved survival in adenocarcinoma
18d ago
ONC
BeOne Medicines price target raised to $367 from $364 at Leerink
PremiumThe Fly
BeOne Medicines price target raised to $367 from $364 at Leerink
1M ago
ONC
BeOne Wins First-in-Class U.S. FDA Nod for BCL2 Drug in Relapsed Mantle Cell Lymphoma
PremiumCompany Announcements
BeOne Wins First-in-Class U.S. FDA Nod for BCL2 Drug in Relapsed Mantle Cell Lymphoma
1M ago
6160
BeOne Medicines’ Beqalzi granted accelerated approval by FDA
PremiumThe Fly
BeOne Medicines’ Beqalzi granted accelerated approval by FDA
1M ago
ONC
BeOne Medicines Grants New RSUs to 201 Employees Under Equity Incentive Plan
PremiumCompany AnnouncementsBeOne Medicines Grants New RSUs to 201 Employees Under Equity Incentive Plan
1M ago
6160
BeOne Medicines price target raised to $395 from $389 at Morgan Stanley
Premium
The Fly
BeOne Medicines price target raised to $395 from $389 at Morgan Stanley
1M ago
ONC
BeOne Medicines price target raised to $409 from $405 at Barclays
Premium
The Fly
BeOne Medicines price target raised to $409 from $405 at Barclays
1M ago
ONC
BeOne Medicines price target raised to $420 from $410 at Guggenheim
PremiumThe Fly
BeOne Medicines price target raised to $420 from $410 at Guggenheim
1M ago
ONC
BeOne Medicines reports Q1 adjusted EPS $3.24 vs. $1.22 last year
PremiumThe Fly
BeOne Medicines reports Q1 adjusted EPS $3.24 vs. $1.22 last year
1M ago
ONC
BeOne Medicines raises FY26 revenue view to $6.3B-$6.5B from $6.2B-$6.4B
PremiumThe Fly
BeOne Medicines raises FY26 revenue view to $6.3B-$6.5B from $6.2B-$6.4B
1M ago
ONC
BeOne Medicines Files U.S. Shelf Registration to Expand Capital Market Access
PremiumCompany Announcements
BeOne Medicines Files U.S. Shelf Registration to Expand Capital Market Access
1M ago
6160
BeOne Medicines Files Form S-3 to Expand U.S. Capital Market Access
PremiumCompany AnnouncementsBeOne Medicines Files Form S-3 to Expand U.S. Capital Market Access
1M ago
6160
BeOne Medicines Issues Q1 2026 Unaudited Results and Cautious Guidance
Premium
Company Announcements
BeOne Medicines Issues Q1 2026 Unaudited Results and Cautious Guidance
1M ago
6160
BeOne Medicines Highlights Global Footprint With Latest Form 10-Q Filing
Premium
Company Announcements
BeOne Medicines Highlights Global Footprint With Latest Form 10-Q Filing
1M ago
6160

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >